Safety and Efficacy of SAB-185 for Non-hospitalized Adults with COVID-19: A Randomized Clinical Trial

By sjmartinez • July 20, 2024

Chew KW, Taiwo BO, Moser C, Daar ES, Wohl DA, Ritz J, Javan AC, Li JZ, Fischer W, Greninger AL, Bausch C, Luke T, Call R, Neytman G, Giganti MJ, Fletcher CV, Hughes MD, Eron JJ, Currier JS, Smith DM; ACTIV-2/A5401 Study Team. Safety and Efficacy of SAB-185 for Non-hospitalized Adults with COVID-19: A Randomized Clinical Trial. J Infect Dis. 2024 Jul 20:jiae369. doi: 10.1093/infdis/jiae369. Epub ahead of print. PMID: 39028902.

Tags: ACTIV-2, casirivimab/imdevimab, Clinical Trial, covid-19, Harbor UCLA, Infectious Diseases, outpatient treatment, polyclonal antibodies, Publications, SAB-185, transchromosomic

Related Posts

A rare case of May-Thurner syndrome due to external compression of the right and left common iliac veins

Schwarzman L, Aguilar J, Megowan N. A rare case of May-Thurner syndrome due to external compression of the right and left common iliac veins. J[...]

Advancing Equitable Kidney Care through Population Health Approaches in Los Angeles County’s Safety Net System

Kalantar-Zadeh K, Raff EA, Chong CC, Yang JK, Le TK, Barba LM, Pham PC, Dhamija R, Ghaffari A, Khine A, Patel N, Nicholas SB, Sim[...]

Prevalence and Outcomes of Chronic Kidney Disease-Associated Pruritus: International Results from Peritoneal Dialysis Outcomes and Practice Patterns Study

Tennankore KK, McCullough K, Bieber B, Cho Y, Johnson DW, Kanjanabuch T, Kawanishi H, Kim YL, Lambie M, Rigatto C, Shen J, Schreiber M, Perl[...]